HRP20120490T1 - Spojevi za inhibiciju napredovanja mitoze - Google Patents
Spojevi za inhibiciju napredovanja mitoze Download PDFInfo
- Publication number
- HRP20120490T1 HRP20120490T1 HRP20120490TT HRP20120490T HRP20120490T1 HR P20120490 T1 HRP20120490 T1 HR P20120490T1 HR P20120490T T HRP20120490T T HR P20120490TT HR P20120490 T HRP20120490 T HR P20120490T HR P20120490 T1 HRP20120490 T1 HR P20120490T1
- Authority
- HR
- Croatia
- Prior art keywords
- aliphatic
- group
- fluoroaliphatic
- compound according
- fluoro
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title claims abstract 19
- 230000002401 inhibitory effect Effects 0.000 title claims 2
- 230000008600 mitotic progression Effects 0.000 title 1
- 125000001931 aliphatic group Chemical group 0.000 claims abstract 14
- 125000000623 heterocyclic group Chemical group 0.000 claims abstract 10
- 125000005843 halogen group Chemical group 0.000 claims abstract 6
- 229910052739 hydrogen Inorganic materials 0.000 claims abstract 6
- 239000001257 hydrogen Substances 0.000 claims abstract 6
- 125000001072 heteroaryl group Chemical group 0.000 claims abstract 5
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims abstract 5
- 125000004433 nitrogen atom Chemical group N* 0.000 claims abstract 5
- 150000003839 salts Chemical class 0.000 claims abstract 5
- 125000001153 fluoro group Chemical group F* 0.000 claims abstract 4
- 229910052757 nitrogen Inorganic materials 0.000 claims abstract 3
- 125000001424 substituent group Chemical group 0.000 claims abstract 3
- 125000002947 alkylene group Chemical group 0.000 claims abstract 2
- -1 -OH Chemical group 0.000 claims 6
- 102000003989 Aurora kinases Human genes 0.000 claims 5
- 108090000433 Aurora kinases Proteins 0.000 claims 5
- 125000003118 aryl group Chemical group 0.000 claims 4
- 206010028980 Neoplasm Diseases 0.000 claims 3
- 201000011510 cancer Diseases 0.000 claims 3
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims 3
- 125000001309 chloro group Chemical group Cl* 0.000 claims 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 125000002541 furyl group Chemical group 0.000 claims 2
- 230000001404 mediated effect Effects 0.000 claims 2
- 238000000034 method Methods 0.000 claims 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 2
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 2
- 125000001544 thienyl group Chemical group 0.000 claims 2
- 125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 claims 2
- 125000006570 (C5-C6) heteroaryl group Chemical group 0.000 claims 1
- SRFVRJILPIASPG-UHFFFAOYSA-N 4-[[7-(2-fluoro-6-methoxyphenyl)-9-(1-methylpyrrol-2-yl)-5h-pyrimido[5,4-d][2]benzazepin-2-yl]amino]-2-methoxybenzoic acid Chemical compound C1=C(C(O)=O)C(OC)=CC(NC=2N=C3C4=CC=C(C=C4C(=NCC3=CN=2)C=2C(=CC=CC=2F)OC)C=2N(C=CC=2)C)=C1 SRFVRJILPIASPG-UHFFFAOYSA-N 0.000 claims 1
- ZLHFILGSQDJULK-UHFFFAOYSA-N 4-[[9-chloro-7-(2-fluoro-6-methoxyphenyl)-5H-pyrimido[5,4-d][2]benzazepin-2-yl]amino]-2-methoxybenzoic acid Chemical compound C1=C(C(O)=O)C(OC)=CC(NC=2N=C3C4=CC=C(Cl)C=C4C(=NCC3=CN=2)C=2C(=CC=CC=2F)OC)=C1 ZLHFILGSQDJULK-UHFFFAOYSA-N 0.000 claims 1
- NRJOLMQQQLDIPP-UHFFFAOYSA-N 4-[[9-ethynyl-7-(2-fluoro-6-methoxyphenyl)-5h-pyrimido[5,4-d][2]benzazepin-2-yl]amino]-2-methoxybenzoic acid Chemical compound C1=C(C(O)=O)C(OC)=CC(NC=2N=C3C4=CC=C(C=C4C(=NCC3=CN=2)C=2C(=CC=CC=2F)OC)C#C)=C1 NRJOLMQQQLDIPP-UHFFFAOYSA-N 0.000 claims 1
- 102000004000 Aurora Kinase A Human genes 0.000 claims 1
- 108090000461 Aurora Kinase A Proteins 0.000 claims 1
- 206010006187 Breast cancer Diseases 0.000 claims 1
- 208000026310 Breast neoplasm Diseases 0.000 claims 1
- 125000006519 CCH3 Chemical group 0.000 claims 1
- 206010009944 Colon cancer Diseases 0.000 claims 1
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 1
- 206010033128 Ovarian cancer Diseases 0.000 claims 1
- 206010061535 Ovarian neoplasm Diseases 0.000 claims 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims 1
- 206010060862 Prostate cancer Diseases 0.000 claims 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims 1
- 208000005718 Stomach Neoplasms Diseases 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 230000000694 effects Effects 0.000 claims 1
- 125000000219 ethylidene group Chemical group [H]C(=[*])C([H])([H])[H] 0.000 claims 1
- 125000002534 ethynyl group Chemical group [H]C#C* 0.000 claims 1
- 125000001207 fluorophenyl group Chemical group 0.000 claims 1
- 206010017758 gastric cancer Diseases 0.000 claims 1
- 125000005842 heteroatom Chemical group 0.000 claims 1
- 238000000338 in vitro Methods 0.000 claims 1
- 230000005764 inhibitory process Effects 0.000 claims 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 1
- 229910052760 oxygen Inorganic materials 0.000 claims 1
- 201000002528 pancreatic cancer Diseases 0.000 claims 1
- 208000008443 pancreatic carcinoma Diseases 0.000 claims 1
- 125000000719 pyrrolidinyl group Chemical group 0.000 claims 1
- AIUYVPGHBMKGAC-UHFFFAOYSA-M sodium;4-[[9-chloro-7-(2-fluoro-6-methoxyphenyl)-5h-pyrimido[5,4-d][2]benzazepin-2-yl]amino]-2-methoxybenzoate Chemical compound [Na+].C1=C(C([O-])=O)C(OC)=CC(NC=2N=C3C4=CC=C(Cl)C=C4C(=NCC3=CN=2)C=2C(=CC=CC=2F)OC)=C1 AIUYVPGHBMKGAC-UHFFFAOYSA-M 0.000 claims 1
- 201000011549 stomach cancer Diseases 0.000 claims 1
- 229910052717 sulfur Inorganic materials 0.000 claims 1
- 229940124597 therapeutic agent Drugs 0.000 claims 1
- 125000003944 tolyl group Chemical group 0.000 claims 1
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims 1
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Enzymes And Modification Thereof (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US85934006P | 2006-11-16 | 2006-11-16 | |
| PCT/US2007/023948 WO2008063525A1 (fr) | 2006-11-16 | 2007-11-14 | Composés destinés à inhiber la progression mitotique |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20120490T1 true HRP20120490T1 (hr) | 2012-07-31 |
Family
ID=39315133
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20120490TT HRP20120490T1 (hr) | 2006-11-16 | 2012-06-12 | Spojevi za inhibiciju napredovanja mitoze |
| HRP20150047TT HRP20150047T1 (en) | 2006-11-16 | 2015-01-13 | Compound for inhibiting mitotic progression |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20150047TT HRP20150047T1 (en) | 2006-11-16 | 2015-01-13 | Compound for inhibiting mitotic progression |
Country Status (35)
| Country | Link |
|---|---|
| US (6) | US8026246B2 (fr) |
| EP (4) | EP2497773B1 (fr) |
| JP (3) | JP5102839B2 (fr) |
| KR (2) | KR101342014B1 (fr) |
| CN (2) | CN103483343B (fr) |
| AR (1) | AR064246A1 (fr) |
| AT (1) | ATE556076T1 (fr) |
| AU (1) | AU2007322046B2 (fr) |
| BR (1) | BRPI0718803B8 (fr) |
| CA (1) | CA2669680C (fr) |
| CL (1) | CL2007003244A1 (fr) |
| CR (3) | CR10782A (fr) |
| CY (1) | CY1112828T1 (fr) |
| DK (2) | DK2086981T3 (fr) |
| EA (1) | EA015779B1 (fr) |
| ES (3) | ES2384123T3 (fr) |
| GE (1) | GEP20125459B (fr) |
| HK (4) | HK1134672A1 (fr) |
| HR (2) | HRP20120490T1 (fr) |
| IL (1) | IL198690A0 (fr) |
| MA (1) | MA30988B1 (fr) |
| MX (3) | MX2009004670A (fr) |
| MY (1) | MY153243A (fr) |
| NO (1) | NO343338B1 (fr) |
| NZ (3) | NZ597252A (fr) |
| PH (1) | PH12012502057A1 (fr) |
| PL (2) | PL2086981T3 (fr) |
| PT (2) | PT2086981E (fr) |
| RS (2) | RS53788B1 (fr) |
| SG (2) | SG176443A1 (fr) |
| SI (2) | SI2497772T1 (fr) |
| TW (1) | TWI401255B (fr) |
| UA (1) | UA94129C2 (fr) |
| WO (1) | WO2008063525A1 (fr) |
| ZA (1) | ZA200903279B (fr) |
Families Citing this family (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RS50568B8 (sr) | 2004-05-14 | 2019-08-30 | Millennium Pharm Inc | Jedinjenja i postupci za inhibiciju mitotičke progresije inhibiranjem aurora kinaze |
| CL2007003244A1 (es) * | 2006-11-16 | 2008-04-04 | Millennium Pharm Inc | Compuestos derivados de pirimido[5,4-d][2]benzazepina; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento del cancer. |
| US7998952B2 (en) * | 2008-12-05 | 2011-08-16 | Millennium Pharmaceuticals, Inc. | Thiolactams and uses thereof |
| AU2009330727B2 (en) * | 2008-12-22 | 2016-07-28 | Millennium Pharmaceuticals, Inc. | Combination of Aurora kinase inhibitors and anti-CD20 antibodies |
| JO3635B1 (ar) * | 2009-05-18 | 2020-08-27 | Millennium Pharm Inc | مركبات صيدلانية صلبة وطرق لانتاجها |
| JO3434B1 (ar) | 2009-07-31 | 2019-10-20 | Millennium Pharm Inc | مركبات صيدلانية لمعالجة السرطان وامراض واضطرابات اخري |
| US8653064B2 (en) | 2010-02-19 | 2014-02-18 | Millennium Pharmaceuticals, Inc. | Crystalline forms of sodium 4-{[9-chloro-7-(2-fluoro-6-methoxyphenyl)-5H-pyrimido[5,4-D][2]benzazepin-2-yl]amino}-2-methoxybenzoate |
| US20120107304A1 (en) | 2010-04-27 | 2012-05-03 | Boehringer Ingelheim International Gmbh | Combination therapy in treatment of oncological and fibrotic diseases |
| ES2526671T3 (es) * | 2010-06-22 | 2015-01-14 | Glaxosmithkline Llc | Compuestos de benzotriazoldiazepina inhibidores de bromodominios |
| TW201316991A (zh) | 2011-06-03 | 2013-05-01 | Millennium Pharm Inc | Ｍｅｋ抑制劑與奧諾拉（ａｕｒｏｒａ）ａ激酶選擇性抑制劑之組合 |
| US20130303519A1 (en) | 2012-03-20 | 2013-11-14 | Millennium Pharmaceuticals, Inc. | Methods of treating cancer using aurora kinase inhibitors |
| CN103772391A (zh) * | 2012-10-23 | 2014-05-07 | 杨子娇 | 一类治疗房角狭窄的化合物及其用途 |
| WO2014153509A1 (fr) | 2013-03-22 | 2014-09-25 | Millennium Pharmaceuticals, Inc. | Combinaison d'inhibiteurs catalytiques de mtorc1/2 et inhibiteurs sélectifs de la kinase aurora a |
| WO2015085289A1 (fr) | 2013-12-06 | 2015-06-11 | Millennium Pharmaceuticals, Inc. | Combinaison d'inhibiteurs de kinase aurora et d'anticorps anti-cd30 |
| CN107205933A (zh) * | 2014-12-23 | 2017-09-26 | 米伦纽姆医药公司 | Raf抑制剂与aurora激酶抑制剂的组合 |
| CA2997784A1 (fr) | 2015-09-09 | 2017-03-16 | Icahn School Of Medicine At Mount Sinai | Sulfonamides heterocycliques tricycliques contraints en tant qu'agents anti-cancereux |
| CN108349943A (zh) | 2015-09-09 | 2018-07-31 | 西奈山伊坎医学院 | 杂环受限三环磺酰胺作为抗癌试剂 |
| WO2017146253A1 (fr) | 2016-02-26 | 2017-08-31 | 公益財団法人がん研究会 | Procédé de criblage d'agent anticancéreux focalisé sur la fonction de hp1, et système d'évaluation |
| KR102511024B1 (ko) | 2016-03-15 | 2023-03-16 | 오리존 지노믹스 에스.에이. | 고형 종양의 치료에 사용하기 위한 lsd1 억제제의 조합물 |
| JP6188986B1 (ja) * | 2017-03-23 | 2017-08-30 | 株式会社ノエビア | 時計遺伝子発現量調整剤及びエラスチン産生促進剤 |
| WO2019195658A1 (fr) | 2018-04-05 | 2019-10-10 | Dana-Farber Cancer Institute, Inc. | Niveaux sting comme biomarqueur pour l'immunothérapie du cancer |
| WO2020049208A1 (fr) | 2018-09-09 | 2020-03-12 | Fundacio Privada Institut De Recerca De La Sida - Caixa | Aurora cinasa comme cible pour traiter, prévenir ou soigner une infection par vih ou le sida |
| WO2021041532A1 (fr) | 2019-08-26 | 2021-03-04 | Dana-Farber Cancer Institute, Inc. | Utilisation d'héparine pour favoriser la signalisation de l'interféron de type 1 |
| WO2023196959A1 (fr) | 2022-04-07 | 2023-10-12 | Eli Lilly And Company | Procédé de fabrication d'un inhibiteur de kras g12c |
| WO2023196887A1 (fr) | 2022-04-08 | 2023-10-12 | Eli Lilly And Company | Méthode de traitement comprenant des inhibiteurs de kras g12c et des inhibiteurs d'aurora a |
| WO2024006424A1 (fr) | 2022-06-30 | 2024-01-04 | Eli Lilly And Company | Inhibiteur de kras g12c pour le traitement du cancer |
Family Cites Families (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4099012A (en) | 1975-08-28 | 1978-07-04 | Ciba-Geigy Corporation | 2-pyrazolyl-benzophenones |
| IL59316A (en) | 1979-02-07 | 1983-07-31 | Sparamedica Ag | Phenylpyrimidobenzazepine derivatives,their preparation and pharmaceutical compositions containing them |
| US4481142A (en) | 1979-02-07 | 1984-11-06 | Hoffmann-La Roche Inc. | Pyrimido-2-benzazepines |
| US4469633A (en) | 1980-05-16 | 1984-09-04 | Hoffmann-La Roche Inc. | N-oxides of 5-oxo-1-phenyl-2-benzazepines |
| EP0273697A3 (fr) | 1986-12-30 | 1989-11-29 | Merck & Co. Inc. | 2-Benzazépines à cycles hétérocycliques de 5 et 6 côtés |
| US5166151A (en) | 1988-03-25 | 1992-11-24 | Merck & Co., Inc. | 2-Benzazepines with 5- and 6-membered heterocyclic rings, compositions and medical methods of use thereof |
| US5210082A (en) | 1991-05-16 | 1993-05-11 | Merck & Co., Inc. | 2-benzazepines with 5- and 6-membered heterocyclic rings to treat pain and anxiety disorders |
| GB9523675D0 (en) | 1995-11-20 | 1996-01-24 | Celltech Therapeutics Ltd | Chemical compounds |
| KR19990087585A (ko) | 1996-03-08 | 1999-12-27 | 돈 리사 로얄 | 신경학적 활성제로서의 아졸로벤즈아제핀 유도체 |
| AU5330698A (en) | 1996-12-23 | 1998-07-17 | Celltech Therapeutics Limited | Fused polycyclic 2-aminopyrimidine derivatives, their preparation and their use as protein tyrosine kinase inhibitors |
| GB9713087D0 (en) | 1997-06-20 | 1997-08-27 | Celltech Therapeutics Ltd | Chemical compounds |
| EP1026167B1 (fr) | 1997-09-29 | 2003-03-05 | Meiji Seika Kaisha Ltd. | Derives de triazolobenzazepine tricyclique, leur procede de production et agents antiallergiques |
| US6277844B1 (en) | 1998-09-14 | 2001-08-21 | Sydney Spector | Compound for selective treatment of malignant cells by inhibiting cell cycle progression, decreasing Bcl2, and increasing apoptosis |
| US6417207B1 (en) | 1999-05-12 | 2002-07-09 | Nitromed, Inc. | Nitrosated and nitrosylated potassium channel activators, compositions and methods of use |
| DE60039782D1 (de) | 1999-12-06 | 2008-09-18 | Ajinomoto Kk | Amidinophenylbrenztraubensäure-derivat |
| ES2265452T3 (es) | 2000-12-21 | 2007-02-16 | Vertex Pharmaceuticals Incorporated | Compuestos de pirazol utiles como inhibidores de la proteina quinasa. |
| US6686352B2 (en) | 2001-05-18 | 2004-02-03 | Hoffmann-La Roche Inc. | Substituted imidazo [1,5-a] pyrimido [5,4-d] [1] benzazepine derivatives |
| DE10135457A1 (de) * | 2001-07-20 | 2003-02-06 | Adc Automotive Dist Control | Optische Sensoranordnung |
| JP4364637B2 (ja) | 2001-08-09 | 2009-11-18 | アクテリオン ファーマシューティカルズ リミテッド | 新規なベンゾ縮合へテロ環化合物 |
| CN1897950A (zh) | 2003-10-14 | 2007-01-17 | 惠氏公司 | 稠合芳基和杂芳基衍生物及其使用方法 |
| RS50568B8 (sr) | 2004-05-14 | 2019-08-30 | Millennium Pharm Inc | Jedinjenja i postupci za inhibiciju mitotičke progresije inhibiranjem aurora kinaze |
| CA2587427A1 (fr) | 2004-11-17 | 2006-05-26 | Miikana Therapeutics, Inc. | Inhibiteurs de kinase |
| WO2006070198A1 (fr) | 2004-12-30 | 2006-07-06 | Astex Therapeutics Limited | Derives pyrazoliques modulant l'activite des kinases cdk, gsk et aurora |
| MX2008008320A (es) | 2005-12-23 | 2008-09-03 | Smithkline Beecham Corp | Inhibidores de azaindol de aurora cinasas. |
| JP2010500352A (ja) | 2006-08-09 | 2010-01-07 | ミレニアム・ファーマシューティカルズ・インコーポレイテッド | 有糸分裂の進行を阻止するためのピリドベンゾアゼピン化合物および方法 |
| CL2007003244A1 (es) | 2006-11-16 | 2008-04-04 | Millennium Pharm Inc | Compuestos derivados de pirimido[5,4-d][2]benzazepina; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento del cancer. |
| JO3635B1 (ar) | 2009-05-18 | 2020-08-27 | Millennium Pharm Inc | مركبات صيدلانية صلبة وطرق لانتاجها |
-
2007
- 2007-11-09 CL CL200703244A patent/CL2007003244A1/es unknown
- 2007-11-14 CN CN201310367332.9A patent/CN103483343B/zh active Active
- 2007-11-14 GE GEAP200711309A patent/GEP20125459B/en unknown
- 2007-11-14 PT PT07867449T patent/PT2086981E/pt unknown
- 2007-11-14 TW TW096143087A patent/TWI401255B/zh active
- 2007-11-14 ES ES07867449T patent/ES2384123T3/es active Active
- 2007-11-14 NZ NZ597252A patent/NZ597252A/xx unknown
- 2007-11-14 SI SI200731591T patent/SI2497772T1/sl unknown
- 2007-11-14 KR KR1020117022355A patent/KR101342014B1/ko active IP Right Grant
- 2007-11-14 RS RS20150047A patent/RS53788B1/en unknown
- 2007-11-14 MY MYPI20091846A patent/MY153243A/en unknown
- 2007-11-14 RS RS20120247A patent/RS52313B/en unknown
- 2007-11-14 NZ NZ611898A patent/NZ611898A/en not_active IP Right Cessation
- 2007-11-14 SG SG2011080652A patent/SG176443A1/en unknown
- 2007-11-14 SG SG10201503350TA patent/SG10201503350TA/en unknown
- 2007-11-14 NZ NZ577042A patent/NZ577042A/en unknown
- 2007-11-14 EP EP12153134.7A patent/EP2497773B1/fr active Active
- 2007-11-14 SI SI200730975T patent/SI2086981T1/sl unknown
- 2007-11-14 EP EP15155821.0A patent/EP2944639B1/fr active Active
- 2007-11-14 CA CA2669680A patent/CA2669680C/fr active Active
- 2007-11-14 KR KR1020097012501A patent/KR101110458B1/ko active IP Right Grant
- 2007-11-14 MX MX2009004670A patent/MX2009004670A/es active IP Right Grant
- 2007-11-14 EA EA200970486A patent/EA015779B1/ru unknown
- 2007-11-14 PL PL07867449T patent/PL2086981T3/pl unknown
- 2007-11-14 AT AT07867449T patent/ATE556076T1/de active
- 2007-11-14 PT PT121531313T patent/PT2497772E/pt unknown
- 2007-11-14 UA UAA200906211A patent/UA94129C2/ru unknown
- 2007-11-14 ES ES12153134.7T patent/ES2537451T3/es active Active
- 2007-11-14 DK DK07867449.6T patent/DK2086981T3/da active
- 2007-11-14 CN CN2007800423837A patent/CN101547924B/zh active Active
- 2007-11-14 ZA ZA200903279A patent/ZA200903279B/xx unknown
- 2007-11-14 DK DK12153131.3T patent/DK2497772T3/en active
- 2007-11-14 MX MX2012011396A patent/MX348568B/es unknown
- 2007-11-14 AU AU2007322046A patent/AU2007322046B2/en active Active
- 2007-11-14 BR BRPI0718803A patent/BRPI0718803B8/pt active IP Right Grant
- 2007-11-14 EP EP12153131.3A patent/EP2497772B1/fr active Active
- 2007-11-14 PL PL12153131T patent/PL2497772T3/pl unknown
- 2007-11-14 JP JP2009537199A patent/JP5102839B2/ja active Active
- 2007-11-14 MX MX2012011398A patent/MX343391B/es unknown
- 2007-11-14 EP EP07867449A patent/EP2086981B1/fr active Active
- 2007-11-14 ES ES12153131.3T patent/ES2528793T3/es active Active
- 2007-11-14 WO PCT/US2007/023948 patent/WO2008063525A1/fr active Application Filing
- 2007-11-14 US US11/985,277 patent/US8026246B2/en active Active
- 2007-11-16 AR ARP070105104A patent/AR064246A1/es unknown
-
2009
- 2009-05-08 CR CR10782A patent/CR10782A/es unknown
- 2009-05-11 IL IL198690A patent/IL198690A0/en active IP Right Grant
- 2009-05-13 NO NO20091864A patent/NO343338B1/no unknown
- 2009-06-12 MA MA31985A patent/MA30988B1/fr unknown
-
2010
- 2010-02-11 HK HK10101590.0A patent/HK1134672A1/xx unknown
-
2011
- 2011-08-25 US US13/217,659 patent/US20110312942A1/en not_active Abandoned
- 2011-08-25 US US13/217,729 patent/US9988384B2/en active Active
- 2011-08-30 JP JP2011187930A patent/JP5452811B2/ja active Active
-
2012
- 2012-06-06 CY CY20121100518T patent/CY1112828T1/el unknown
- 2012-06-12 HR HRP20120490TT patent/HRP20120490T1/hr unknown
- 2012-10-12 PH PH12012502057A patent/PH12012502057A1/en unknown
-
2013
- 2013-03-08 HK HK13102944.8A patent/HK1175777A1/xx unknown
- 2013-03-11 HK HK13102986.7A patent/HK1175778A1/xx unknown
- 2013-11-15 JP JP2013236439A patent/JP2014055166A/ja active Pending
-
2014
- 2014-04-04 CR CR20140154A patent/CR20140154A/es unknown
- 2014-10-15 US US14/514,687 patent/US9765076B2/en active Active
- 2014-11-27 CR CR20140544A patent/CR20140544A/es unknown
-
2015
- 2015-01-13 HR HRP20150047TT patent/HRP20150047T1/hr unknown
-
2016
- 2016-05-17 HK HK16105677.1A patent/HK1217699A1/zh unknown
-
2018
- 2018-06-01 US US15/996,166 patent/US10836766B2/en active Active
-
2020
- 2020-11-16 US US17/099,266 patent/US11958855B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20120490T1 (hr) | Spojevi za inhibiciju napredovanja mitoze | |
| RU2345996C1 (ru) | Аннелированные азагетероциклические амиды, включающие пиримидиновый фрагмент, способ их получения и применения | |
| ES2970074T3 (es) | Inhibidor de ATR y su aplicación | |
| JP2010510215A5 (fr) | ||
| ES2668834T3 (es) | Pirimidinas macrociclicas como inhibidores de proteína quinasas | |
| RU2470936C2 (ru) | Соединения-ингибиторы фосфоинозитид 3-киназы и способы применения | |
| HRP20131051T1 (hr) | Inhibitori proteinskih kinaza | |
| HRP20120785T1 (hr) | Spojevi i postupci za inhibiciju napredovanja mitoze putem inhibicije aurora kinaze | |
| HRP20160967T1 (hr) | Heterociklički spojevi korisni kao pdk1 inhibitori | |
| HRP20140437T1 (hr) | Bicikliäśki spojevi i njihove uporabe kao dualnih c-src/jak inhibitora | |
| ATE361916T1 (de) | Pyrimidine verbindungen | |
| HRP20090459T1 (hr) | Aminofenil derivati kao novi inhibitori histonskih deacetilaza | |
| CN102089312A (zh) | 作为蛋白酶体抑制剂的Salinosporamide衍生物 | |
| RU2341527C1 (ru) | Аннелированные азагетероциклы, включающие пиримидиновый фрагмент, способ их получения и ингибиторы pi3k киназ | |
| EA201991025A1 (ru) | Липосомальный препарат для применения для лечения злокачественного новообразования | |
| RU2007125661A (ru) | Арилоксиэтиламиновые и фенилпиперазиновые производные с сочетанием свойств неполного агонизма к рецепторам дофимина-d2 и ингибирования повторного поглощения серотонина | |
| RU2005135338A (ru) | Замещенные 3-цианотиофенацетамиды в качестве антагонистов рецептора глюкагона | |
| AR086100A1 (es) | Compuestos de cromenona y composiciones farmaceuticas que los contienen | |
| CN103483345A (zh) | Pi3k 激酶抑制剂、包含其的药物组合物及其应用 | |
| AR054863A1 (es) | DERIVADOS DE 1H-PIRROLO[3, 4-C]PIRAZOL, UN PROCESO PARA SU PREPARACION, COMPOSICIONES FARMACEUTICAS QUE LOS COMPRENDEN Y SU USO EN LA FABRICACION DE UN MEDICAMENTO PARA EL TRATAMIENTO O PROFILAXIS DE ENFERMEDADES ASOCIADAS CON EL FACTOR DE COAGULACIoN XA | |
| NO20070837L (no) | Pyrido-pyrido pyrimidinderivater, fremstilling derav samt terapeutisk anvendelse for behandling av cancer. | |
| JP2016501185A5 (fr) | ||
| KR101129088B1 (ko) | Ｎ-［6-(시스-2,6-디메틸모르폴린-4-일)피리딘-3-일］-2-메틸-4'-(트리플루오로메톡시)［1,1'-비페닐］-3-카르복스아미드의 염 | |
| WO2010002779A2 (fr) | Naphtyridininones en tant qu’inhibiteurs d’aurora kinase | |
| JP2014524449A5 (fr) |